{
    "clinical_study": {
        "@rank": "33560", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "KHK4577", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is an randomized double-blind placebo-controlled study to evaluate the efficacy\n      and the safety of oral KHK4577 for 6 weeks in patients with atopic dermatitis.\n      Pharmacokinetics of KHK4577 will also be assessed."
        }, 
        "brief_title": "Phase 2 Study of KHK4577", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has signed voluntarily the written informed consent form to participate in\n             this study.\n\n          -  Subject has been diagnosed as atopic dermatitis according to Guidelines for\n             Management of Atopic Dermatitis (2009).\n\n          -  Rajka & Langeland criteria of >/= 4.5 at screening visit\n\n          -  Investigator's Global Assessment (IGA) score of >/= 3 at screening visit\n\n        Exclusion Criteria:\n\n          -  Evidence of skin disorders/conditions that would interfere with the assessment of the\n             effect of the study drug.\n\n          -  Subject received photochemotherapy or systemic immunosuppressants within 2 weeks\n             prior to informed consent.\n\n          -  Subject has any active infectious disease(except localized infection) which needs to\n             treat with systemic antibiotics(eg. antibacterial, antifungal or antiviral drugs)\n             within 4 weeks prior to informed consent.\n\n          -  Subject has complications / history of drug abuse or alcoholism.\n\n          -  Subject has drug allergy or history of allergic reaction to a drug medicine.\n\n          -  Subject has a significant concurrent medical conditions as defined in the study\n             protocol.\n\n          -  Subject is breast-feeding, pregnant or planning to become pregnant in this study\n             period."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004119", 
            "org_study_id": "4577-002"
        }, 
        "intervention": {
            "arm_group_label": "KHK4577", 
            "description": "\"Placebo Experimental : KHK4577\"", 
            "intervention_name": "KHK4577", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 3, 2013", 
        "location": {
            "contact": {
                "email": "clinical.info@kyowa-kirin.co.jp", 
                "last_name": "KYOWA HAKKO KIRIN"
            }, 
            "facility": {
                "address": {
                    "city": "Sapporo", 
                    "country": "Japan", 
                    "state": "Hokkaido", 
                    "zip": "060-0063"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Double-blind Placebo-controlled Study of KHK4577 in Patients With Atopic Dermatitis", 
        "overall_contact": {
            "email": "clinica.info@kyowa-kirin.co.jp", 
            "last_name": "Kyowa Hakko Kirin"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percent improvement from baseline in Eczema Area and Severity Index (EASI)", 
            "safety_issue": "No", 
            "time_frame": "Pre-dose, Week 1,2,4 and 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004119"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in Investigator's Global Assessment score", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, Week 1,2,4 and 6"
            }, 
            {
                "measure": "Dermatology Life Quality Index", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, Week 1,2,4 and 6"
            }, 
            {
                "measure": "Visual Analog Scale (itching)", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, Week 1,2,4 and 6"
            }, 
            {
                "measure": "Incidence of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From Day 1 through Week 6"
            }, 
            {
                "measure": "Profile of pharmacokinetics of plasma KHK4577 concentration", 
                "safety_issue": "No", 
                "time_frame": "pre-dose, Week 1,2,4 and 6"
            }
        ], 
        "source": "Kyowa Hakko Kirin Company, Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kyowa Hakko Kirin Company, Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}